Opportunity Information: Apply for PAR 11 323
Apply for PAR 11 323
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Biomarkers Bridging Pediatric and Adult Therapeutics (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 1, 2013 and posted on Sep 1, 2011.
- Applicants must submit their applications by Aug 1, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments County governments Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Biomarkers Bridging Pediatric and Adult Therapeutics (R03) opportunity (Funding Opportunity Number PAR 11 323) is a National Institutes of Health (NIH) discretionary grant program designed to support small, focused research projects that help translate biomarker advances from adult medicine into pediatric care. The core goal is to encourage applicants to take biomarkers that have already been developed, characterized, or used in adults and adapt them for use in children, where biological differences related to growth and development can make direct translation unreliable without additional study. Projects supported under this announcement are expected to generate early, practical evidence that an adult biomarker can work in pediatric settings, or to define why and how it must be adjusted to be clinically meaningful in children.
The scientific scope centers on applying and validating adult-derived biomarkers for pediatric purposes, especially where they can improve diagnosis, prognosis, and monitoring. That includes using biomarkers to estimate or track disease progression in children, assess toxicity (for example, adverse effects or organ injury related to therapies), and predict or measure response to treatment. In practical terms, a competitive application would typically propose a clear plan to evaluate whether a known adult biomarker performs adequately in pediatric patients, whether pediatric-specific reference ranges are needed, whether age-related physiology changes how the biomarker behaves, and whether the biomarker correlates with outcomes that matter in pediatric disease management. The emphasis is not on inventing entirely new biomarkers from scratch, but on bridging what is already known in adult populations into pediatric therapeutics and clinical decision-making, which can shorten the time it takes for children to benefit from biomarker-driven medicine.
This FOA uses the NIH R03 mechanism, which is generally intended for pilot or feasibility work, proof-of-concept studies, secondary analyses, or other tightly scoped projects that can be completed with modest resources. The listed award ceiling is $50,000, reinforcing that the program is aimed at smaller, well-defined studies rather than large multi-year clinical validation programs. Cost sharing or matching is not required, which can lower barriers for institutions that want to launch early-stage translational work without needing to secure additional mandatory funds.
Eligibility is broad and includes many types of organizations. Domestic applicants may include public and private institutions of higher education, nonprofits (including both 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profit entities), independent school districts, and multiple levels of government such as state, county, city or township governments, special district governments, and certain housing authorities. The announcement also highlights eligibility for a wide range of mission-driven or community-serving institutions and organizations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Importantly, non-U.S. entities (foreign institutions) are eligible to apply, and non-U.S. components of U.S. organizations may also participate; foreign components as defined by NIH policy are allowed, which can be relevant for diseases where pediatric cohorts, biospecimens, or validation settings may be more accessible outside the United States.
Administratively, the opportunity is categorized as a grant under the health-related assistance area, with the CFDA number 93.865 (Child Health and Human Development Extramural Research), indicating strong alignment with pediatric and developmental health priorities. Key dates in the record show a posted date of September 1, 2011, an original closing date of September 7, 2014, and an archive date of September 1, 2013, meaning the specific FOA as listed is no longer active and was formally archived. For the authoritative full text and any related NIH guide notices, the source points to the NIH grants page at http://grants.nih.gov/grants/guide/pa-files/PAR-11-323.html. For technical issues accessing the announcement or linking to it, the contact provided is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this grant opportunity is best understood as a targeted NIH push to reduce the gap between adult and pediatric biomarker science by funding smaller, practical studies that test whether adult biomarkers can reliably inform pediatric diagnosis, prognosis, safety monitoring, and treatment response. The intended outcome is stronger evidence and clearer methods for using biomarkers in children, which can ultimately support more precise pediatric therapeutics and better clinical decision-making across childhood development stages.
Frequently Asked Questions (FAQs)
What is the Biomarkers Bridging Pediatric and Adult Therapeutics (R03) opportunity?
The Biomarkers Bridging Pediatric and Adult Therapeutics (R03) opportunity is an NIH discretionary grant program (Funding Opportunity Number PAR-11-323) designed to support small, focused research projects that help translate biomarker advances from adult medicine into pediatric care.
What is the main goal of this funding opportunity?
The core goal is to encourage researchers to take biomarkers that have already been developed, characterized, or used in adults and adapt them for use in children. Because growth and development can change biology in ways that make direct adult-to-child translation unreliable, supported projects are expected to generate early, practical evidence that an adult biomarker works in pediatric settings or to define how it must be adjusted to be clinically meaningful for children.
What kinds of projects are a good fit for this FOA?
Projects that fit well typically propose a clear plan to evaluate whether a known adult biomarker performs adequately in pediatric patients. Examples of the types of questions a project might address include whether pediatric-specific reference ranges are needed, whether age-related physiological changes affect biomarker behavior, and whether the biomarker correlates with outcomes that matter in pediatric disease management.
Is this FOA meant to fund the discovery of entirely new biomarkers?
No. The emphasis is not on inventing new biomarkers from scratch. The focus is on bridging what is already known from adult populations into pediatric therapeutics and clinical decision-making.
What scientific uses of biomarkers are emphasized under this opportunity?
The scientific scope centers on applying and validating adult-derived biomarkers for pediatric purposes, especially where they can improve diagnosis, prognosis, and monitoring. This includes using biomarkers to estimate or track disease progression in children, assess toxicity (such as adverse effects or organ injury related to therapies), and predict or measure response to treatment.
What type of grant mechanism does this opportunity use?
This FOA uses the NIH R03 mechanism, which is generally intended for small, tightly scoped efforts such as pilot or feasibility work, proof-of-concept studies, and secondary analyses.
How large are the awards under this FOA?
The listed award ceiling is $50,000, reflecting that the program is aimed at modestly resourced, well-defined studies rather than large, multi-year clinical validation programs.
Is cost sharing or matching required?
No. Cost sharing or matching is not required under this opportunity.
Who is eligible to apply?
Eligibility is broad and includes many organization types. Domestic applicants may include public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses), independent school districts, and various government entities such as state, county, city or township governments, special district governments, and certain housing authorities.
Are mission-driven and community-serving institutions included in eligibility?
Yes. The announcement highlights eligibility for institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies.
Are non-U.S. (foreign) organizations allowed to apply?
Yes. Non-U.S. entities (foreign institutions) are eligible to apply. In addition, non-U.S. components of U.S. organizations may participate, and foreign components (as defined by NIH policy) are allowed.
Why does the FOA emphasize bridging adult biomarkers into pediatrics?
The FOA is designed to reduce the gap between adult and pediatric biomarker science. Biological differences related to growth and development can make adult biomarkers unreliable in children without additional study. By supporting targeted projects, the program aims to speed the time it takes for children to benefit from biomarker-driven medicine.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.865 (Child Health and Human Development Extramural Research).
Is this funding opportunity still active?
No. The record shows a posted date of September 1, 2011, an archive date of September 1, 2013, and an original closing date of September 7, 2014. As listed, the FOA is no longer active and was formally archived.
Where can applicants find the authoritative full text of the announcement?
The source provided for the full text and related NIH guide notices is: http://grants.nih.gov/grants/guide/pa-files/PAR-11-323.html
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues, the contact provided is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What outcomes are expected from projects funded under this FOA?
Projects are expected to generate early, practical evidence that an adult biomarker can work in pediatric settings, or to clearly define why and how it must be adjusted to be clinically meaningful in children. The broader intended outcome is stronger evidence and clearer methods for using biomarkers to support pediatric therapeutics and clinical decision-making across childhood development stages.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Biomarkers Bridging Pediatric and Adult Therapeutics (R01)
Previous opportunity: Highways for LIFE Technology Partnerships Program (Request for Information ONLY)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 323
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 323) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIH/PEPFAR Collaboration for Advancing Implementation Science in Prevention of Maternal Child HIV Transmission (PMTCT) (R01) Apply for RFA HD 12 210 Funding Number: RFA HD 12 210 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Research Infrastructure for Demographic and Behavioral Population Science (R24) Apply for RFA HD 12 186 Funding Number: RFA HD 12 186 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Improving Adherence to Treatment Regimens for HIV Positive Adolescents and Young Adults (R01) Apply for RFA HD 12 206 Funding Number: RFA HD 12 206 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $400,000 |
| Developmental Mechanisms of Human Structural Birth Defects (P01) Apply for PAR 12 034 Funding Number: PAR 12 034 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Advanced Neural Prosthetics Research and Development (U01) Apply for PAR 12 053 Funding Number: PAR 12 053 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,000,000 |
| Enhancing Developmental Biology Research at Undergraduate Institutions Academic Research Enhancement Award (R15) Apply for PAR 12 057 Funding Number: PAR 12 057 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $300,000 |
| Specialized Cooperative Centers Program in Reproduction and Infertility Research (U54) Apply for RFA HD 13 005 Funding Number: RFA HD 13 005 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Learning Disabilities Innovation Hubs (R24) Apply for RFA HD 12 203 Funding Number: RFA HD 12 203 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $450,000 |
| Leadership Group for a Clinical Research Network on HIV/AIDS and HIV associated Infections in Pediatric and Maternal Populations (UM1) Apply for RFA AI 12 001 Funding Number: RFA AI 12 001 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV associated Infections in Adults (UM1) Apply for RFA AI 12 004 Funding Number: RFA AI 12 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Leadership Group for a Clinical Research Network on Microbicides to Prevent HIV Infection (UM1) Apply for RFA AI 12 008 Funding Number: RFA AI 12 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biomedical and Behavioral Research Innovations to Ensure Equity (BRITE) in Maternal and Child Health (R15) Apply for PAR 12 093 Funding Number: PAR 12 093 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Academic Community Partnership Conference Series (R13) Apply for PAR 12 102 Funding Number: PAR 12 102 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $30,000 |
| Child Health Research Career Development Award (CHRCDA) Program K12 Apply for RFA HD 13 011 Funding Number: RFA HD 13 011 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $400,000 |
| Limited Competition Revision Applications to Advance Evidence Based Research Related to Protections for Human Subjects (U24) Apply for PAS 12 165 Funding Number: PAS 12 165 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition Revision Applications to Advance Evidence Based Research Related to Protections for Human Subjects (U10) Apply for PAS 12 168 Funding Number: PAS 12 168 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Advanced Tools and Technologies for Cerebrospinal Fluid Shunts SBIR (R43/R44) Apply for PA 12 189 Funding Number: PA 12 189 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Advanced Tools and Technologies for Cerebrospinal Fluid Shunts STTR (R41/R42) Apply for PA 12 190 Funding Number: PA 12 190 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Global Network for Womens and Childrens Health Research (U10) Apply for RFA HD 13 006 Funding Number: RFA HD 13 006 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the NICHD Cooperative Multicenter Maternal Fetal Medicine Units Research Network (U10) Apply for RFA HD 13 013 Funding Number: RFA HD 13 013 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 323", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.